Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands

Takashi Akazawa1 | Toshimitsu Ohashi1,2 | Viskam Wijewardana3 | Kikuya Sugiura3 | Norimitsu Inoue1

1Department of Tumor Immunology, Research Center, Osaka International Cancer Institute, Osaka, Japan
2Department of Otolaryngology, Gifu University Graduate School of Medicine, Gifu City, Japan
3Department of Advanced Pathobiology, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Izumisano, Osaka, Japan

Correspondence
Takashi Akazawa and Norimitsu Inoue, Department of Tumor Immunology, Research Center, Osaka International Cancer Institute, Osaka, Japan. Emails: akazawa-ta@mc.pref.osaka.jp; inoue-no@mc.pref.osaka.jp

Present address
Viskam Wijewardana, Animal Production and Health Laboratory, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, Department of Nuclear Sciences and Applications, International Atomic Energy Agency Laboratories Seibersdorf, Seibersdorf, Austria.

Funding information
Japan Society for the Promotion of Science, KAKENHI Grant Numbers JP 17K08299 to T. Akazawa and JP 16H04703 to N. Inoue.

For a successful tumor vaccine, it is necessary to develop effective immuno-adjuvants and identify specific tumor antigens. Tumor cells obtained from surgical or biopsy tissues are a good source of tumor antigens but, unlike bacteria, they do not induce strong immune responses. Here, we designed 2 novel lipopeptides that coat tumor cell surfaces and mimic bacterial components. Tumor cells coated with these lipopeptides (called bacteria-mimicking tumor cells [BMTC]) were prepared and their efficacy as a tumor vaccine examined. Natural bacterial lipopeptides act as ligands for toll-like receptor 2 (TLR2) and activate dendritic cells (DC). To increase the affinity of the developed lipopeptides for the negatively charged plasma membrane, a cationic polypeptide was connected to Pam2Cys (P2C), which is the basic structure of the TLR2 ligand. This increased the non-specific binding affinity of the peptides for the cell surface. Two such lipopeptides, P2CSK11 (containing 1 serine and 11 lysine residues) and P2CSR11 (containing 1 serine and 11 arginine residues) bound to irradiated tumor cells via the long cationic polypeptides more efficiently than the natural lipopeptide MALP2 (P2C-GNNDESNISFKEK) or a synthetic lipopeptide P2CSK4 (a short cationic polypeptide containing 1 serine and 4 lysines). BMTC coated with P2CSR11 or P2CSK11 were efficiently phagocytosed by DC and induced antigen cross-presentation in vitro. They also induced effective tumor-specific cytotoxic T cell responses and inhibited tumor growth in in vivo mouse models. P2CSR11 activated DC but induced less inflammation-inducing cytokines/interferons than other lipopeptides. Thus, P2CSR11 is a strong candidate antigen-specific immuno-adjuvant, with few adverse effects.

KEYWORDS
adjuvant, bacterial lipopeptide, drug design, toll-like receptor ligand, tumor vaccine

1 INTRODUCTION

Immunotherapy using immune checkpoint inhibitors is an effective anti-tumor treatment.1,2 Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are the most critical effectors against tumor cells; however, during tumorigenesis, tumor cells acquire multiple mechanisms that allow them to attenuate/escape the cytotoxic activity of these effector cells. Accumulation of effector cells at tumor sites is often prevented, and their efficacy is suppressed by negative regulator cells such as myeloid-derived suppressor cells,3 M2-like macrophages4,5 and regulatory T cells.6 The interaction between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CD80/CD86, and between programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1), suppresses T cell proliferation, cytokine production and cytotoxic function.7,8 To overcome such tumor-mediated immunosuppression, it is necessary to develop effective strategies to stimulate tumor-specific effector cells.
We previously developed effective and useful immuno-adjuvants that activate effector cells. We constructed new anti-tumor drugs by altering the structure of a mycoplasma lipopeptide, MALP2, which is the basic component of immuno-adjuvants. MALP2, a natural toll-like receptor 2 (TLR2) ligand, consists of a mycoplasma peptide containing 13 amino acids and an N-terminal cysteine conjugated to 2 palmitate moieties (S-2,3-bis(palmitoyloxy)-propyl-cysteine [Pam2Cys/P2C]). Although natural lipopeptides/TLR2 ligands harbor some peptide sequence motifs that are necessary for biosynthetic processes, these are unnecessary if we generate the lipopeptides by chemical synthesis. However, synthetic lipopeptides must meet essential conditions for TLR2/TLR6 ligand activity (a small amino acid at the 2nd position and a highly hydrophilic peptide sequence). Therefore, to increase anti-tumor immuno-adjuvant activity, we exchanged bacterial peptides for other functional peptide sequences that meet the conditions essential for TLR ligand activity. In a previous report, we named this process of designing and developing synthetic adjuvants “adjuvant engineering.”

Tumor cells and tissues obtained by surgical operation or biopsy are the most suitable antigen sources for constructing a personalized tumor vaccine because they include individual tumor antigens, even if they have not yet been formally identified. This strategy has been developed to generate autologous tumor vaccines. However, most therapies based on tumor antigens, including peptide vaccines, do not show marked therapeutic effects. Bacteria express both TLR ligands and specific antigens; therefore, bacteria activate dendritic cells (DC) directly via TLR; DC then present bacteria-derived peptide antigens to effector cells to induce strong immune responses. Tumor cells alone cannot induce strong immune responses because although tumors express many specific antigens (such as cancer-testis antigens and tumor-specific neoantigens) they do not express TLR ligands. To induce strong immune responses, simple mixtures of TLR ligands and antigens or TLR ligands conjugated with antigen peptide are widely used as vaccines. Another study shows that gram-negative bacteria, such as Salmonella species, expressing identified tumor antigens are useful for tumor immunotherapy. Thus, mimicking bacterial cells/materials may induce strong immune responses to antigens present on the original cells/materials.

Here, we developed cationic lipopeptides that bound electrostatically to negatively charged tumor cell membranes and used them to prepare tumor cells coated with lipopeptides/TLR2 ligands acting as immuno-adjuvants. We then examined the effects of these bacteria-mimicking tumor cells (BMTC) as vaccines to initiate anti-tumor immune responses.

2  MATERIALS AND METHODS

2.1  Mice, cells and reagents

Wild-type and Tr2-/- C57BL/6J mice were purchased from CLEA Japan (Tokyo, Japan) and Oriental BioService (Kyoto, Japan), respectively. OT-I mice were kindly provided by Dr Hiroshi Kosaka (Osaka University). Mice were maintained under specific pathogen-free conditions in the animal facility of Osaka International Cancer Institute. All animal experiments were performed in accordance with institutional guidelines and approved by the Animal Care and Use Committee of our institute (approval number: 16062409).

Ovalbumin (OVA)-expressing EL4 thymoma cells (EG7-OVA cells) were obtained from the American Tissue Culture Collection (Manassas, VA, USA). A murine Wilms tumor 1 (WT1)-expressing acute myeloid leukemia cell line (mWT1-C1498) was kindly provided by Dr H. Sugiyama (Osaka University, Osaka, Japan). YAC-1, a mouse NK target cell line, was kindly provided by Dr T. Seya (Hokkaido University, Sapporo, Japan). RMA-S, a TAP2-deficient subline of RMA (Rauscher leukemia virus-induced lymphoma cell line), was kindly provided by Dr K. Kärre (Karolinska Institute, Sweden). Culture conditions were as previously described. Ovalbumin-expressing RMA-S cells (RMA-S-OVA) were established by co-transfecting cells with a pPB-EGFP-neo PiggyBac vector containing FLAG-tagged OVA cDNA (XM 015282166, c.3484-4357) and pCMV-hyPBase (both plasmids were kindly provided by Dr K. Yusa). Bone marrow-derived DC (BMDC), inguinal lymph node cells and splenocytes were prepared as previously described.

The following peptides and lipopeptides (purity >90%) were customized by Bio-Synthesis (Lewisville, TX, USA) via Biologica (Nagoya, Aichi, Japan). OVA peptide, SIINFEKL; murine WT1 peptide, RMFPNAPYL; bio-SK4 peptide, biotinylated-SKKKK; bio-MALP2 peptide, biotinylated-GNDESNSIFKKE-bio-SR11 peptide, biotinylated-SRRRRRRRRRRR; bio-SK11 peptide, biotinylated-SKKKKKKKKKKKK; P2CSK4 lipopeptide, P2C-SKKKK; MALP2 lipopeptide, P2C-GNDESNSIFKKE; P2CSR11 lipopeptide, P2C-SRRRRRRRRRRR; and P2CSK11 lipopeptide, P2C-SKKKKKKKKKKKK.

2.2  Preparation of bacteria-mimicking tumor cells

Tumor cells were irradiated with X-rays (100 Gy) to prevent proliferation. Prior to use in the phagocytosis assay, tumor cells were cultured for 30 minutes at 37°C with 10 μmol/L carboxyfluorescein diacetate succinimidyl ester (CFSE). One million tumor cells were treated with 100 μmol/L lipopeptide in 100 μL of PBS for 2 hour at 4°C. For the in vivo experiments, mixtures of lipopeptide and irradiated tumor cells were used as the anti-tumor vaccine (the mixture included both cell-bound and free lipopeptides); this is because BMTC coated with a non-adherent lipopeptide such as P2CSK4 would lose vaccine activity after the washing process. To examine the effects of vaccines that do not contain free lipopeptide, BMTC were then washed twice in culture medium to remove free lipopeptide.

2.3  In vitro assays

Bone marrow-derived DC and splenocytes were stimulated with lipopeptides as previously described. The phagocytosis assay was performed using a Phagocytosis Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA). Briefly, BMDC were stimulated with
each lipopeptide for 24 hours and then cultured with Latex Beads-Rabbit IgG-FITC Complex for 6 hours. For the phagocytosis and cross-presentation assays with BMTC, BMDC were cultured with BMTC (BMDC:BMTC ratio = 1:5) for 12 h (phagocytosis) or 24 hours (cross-presentation) and then analyzed by flow cytometry. Flow cytometry and the ELISA were performed as previously described\textsuperscript{9,10} using the following antibodies and kits: FITC-conjugated anti-mouse CD80; phycoerythrin (PE)-conjugated anti-mouse MHC class I molecule k\textsuperscript{b} bound to the peptide SIINFEKL (Kb-SIINFEKL; BioLegend, San Diego, CA, USA); allophycocyanin (APC)-conjugated anti-CD11c (eBioscience, San Diego, CA, USA); and ELISA kits specific for IFN-\(\gamma\) and IL-12p40 (R&D Systems, Minneapolis, MN, USA).

2.4 In vivo and ex vivo mouse models

The in vivo experiments with EG7-OVA and mWT1-C1498 cells were performed as previously described\textsuperscript{9,10}. On Day 0, EG7-OVA cells (1-2 \(\times\) 10\(^6\) cells) and WT1-C1498 (3 \(\times\) 10\(^5\) cells) were transplanted subcutaneously into the back or flank, respectively, of the mice. When the calculated tumor mass reached approximately 0.4-1.0 cm\(^3\), mice were grouped and subjected to the first treatment. The BMTC (50 \(\mu\)L of a mixture containing 10 nmol lipopeptide and 2 \(\times\) 10\(^5\) irradiated tumor cells) were then administered intradermally 3 times over a period of 1 week (BMTC were injected into the skin around the transplanted tumors between Days 9 and 25). When we examine the effects of vaccines after removal of free lipopeptide, the BMTC were administered twice intradermally. A lipopeptide dose of 10 nmol was validated previously using P2CSK4 as a positive control.\textsuperscript{9} An anti-mouse PD-L1 antibody (InVivoMab; 10F.9G2, Bio X Cell, West Lebanon, NH, USA; 200 \(\mu\)g per mouse) was injected intraperitoneally on the same day as the BMTC. Tumor volume was measured as previously described.\textsuperscript{9,10} To measure cytotoxicity, mice harboring EG7-OVA or mWT1-C1498 tumors were treated as described above and, 24 hours after additional administration of the vaccine (for the EG7-OVA model, Day 24; for the WT1-C1498 model, Day 28), splenocytes were harvested. After in vitro culture for 6 days with OVA peptide and IL-2, cytotoxic activity against RMA-S cells pulsed with OVA or WT1 peptide or YAC-1 cells was measured in a Calcein AM (Molecular Probes, Eugene, OR, USA) assay. Target cells were cultured with each effector cell (effector: target ratio, 30:1) for 6 h at 37°C, and specific lysis (expressed as a percentage) was calculated as previously described.\textsuperscript{9,10}

2.5 Statistical analyses

Data are expressed as the mean \(\pm\) SD (for cytokine measurement) or the mean \(\pm\) standard error (SE) (for tumor volume). The significance of differences between groups was analyzed using Student’s \(t\) test (comparison of 2 groups) or 1-way ANOVA with Dunnnett’s test (for multiple comparisons [more than 3 groups]). One-sided \(P\)-values <0.05 were considered statistically significant.

3 RESULTS

To develop novel artificial immuno-adjuvants that can increase the efficacy of personalized vaccines comprising tumor cells as a source of cancer antigens, we linked P2C (a ligand for TLR2) to polypeptides comprising 11 cationic amino acids. As positively charged peptides are attracted electrostatically to the negatively charged plasma membrane of the tumor cell, the lipopeptides coated the tumor cells to yield BMTC, which could then be used as a candidate tumor vaccine (Figure 1A). We prepared 2 novel lipopeptides containing a long cationic sequence: P2CSK11 (P2C-SKKKKKKKKKKK) and P2CSR11 (P2CSRRRRRRRRRRRRR) (Figure 1B). A natural lipopeptide MALP2 (P2C-GNNDESNISFKEK) and a synthetic lipopeptide P2CSK4 (P2C-SKKKK), which has strong anti-tumor activity, were used as controls.\textsuperscript{9,10} First, we examined the affinity of the peptide components of the lipopeptides for RMA-S tumor cells. Irradiated RMA-S cells were incubated with biotinylated peptides and then stained with APC-conjugated streptavidin. The bio-SK4 and bio-MALP2 peptides did not bind to RMA-S cells, whereas the bio-SR11 peptide (at 1, 10 and 100 \(\mu\)mol/L) and bio-SK11 peptides (at 10 and 100 \(\mu\)mol/L) bound to cells in a dose-dependent manner (Figure 1C).

Next, to examine the ability of the lipopeptides to activate DC and splenocytes, we monitored expression of CD80/CD86 (a marker of DC maturation) (Figure 2A,B). We also used the Latex Beads-Rabbit IgG-FITC Complex to measure the phagocytic activity of BMDC stimulated with each lipopeptide (Figure 2C). In contrast to P2CSK4, both P2CSK11 and P2CSR11 activated DC to a similar degree in terms of expression of CD80/CD86 and phagocytic activity. BMDC derived from \(Tlr2^{-/-}\) mice did not respond to the lipopeptides (Figure 2A-C). Furthermore, we examined the ability of BMDC and splenocytes stimulated with the lipopeptides to secrete cytokines. P2CSK11 and P2CSK4 induced similar levels of IL-12p40 production by BMDC, whereas P2CSK11 induced less IFN-\(\gamma\) production by splenocytes than P2CSK4; however, P2CSR11 induced weak production of both cytokines (Figure 2D). No increase in IL-12p40 and IFN-\(\gamma\) production in response to lipopeptides was detected in cells from \(Tlr2^{-/-}\) mice (data not shown).

To examine the effectiveness of BMTC as a tumor vaccine in vitro, we analyzed their ability to induce phagocytosis and cross-presentation by DC. First, irradiated CFSE-labeled RMA-S-OVA cells were preincubated with the lipopeptides and then cultured with BMDC. Increased phagocytosis was detected only in RMA-S cells coated with P2CSK11 or P2CSR11. However, no increase was detected in BMDC derived from \(Tlr2^{-/-}\) or \(Myd88^{-/-}\) mice (Figure 3A). Furthermore, to examine antigen presentation, we detected expression of MHC class I/OVA peptide complexes on the DC surface using a SIINFEKL/H-2K\(^b\)-specific antibody. Both P2CSK11-coated and P2CSR11-coated tumor cells induced antigen cross-presentation by BMDC (Figure 3B). To evaluate cross-presentation, we irradiated RMA-S-OVA cells, preincubated them with the lipopeptides, and then co-cultured them with OT-I splenocytes. Because RMA-S cells lack transporter associated protein 2 (TAP2), they cannot present OVA peptides on MHC class I molecules. Antigen-
presenting cells derived from OT-I splenocytes should engulf OVA-transfected RMA-S cells and present OVA peptides on MHC class I molecules, thereby inducing IFN-γ production by OT-I T cells. The results showed that OT-I splenocytes stimulated with tumor cells coated with P2CSK11 or P2CSR11 produced IFN-γ (Figure 3C).

Next, we examined anti-tumor effects and CTL-induction in vivo mouse models. Mice transplanted with EG7-OVA or mWT1-C1498 cells were treated with the tumor vaccine. In this experiment, a mixture of lipopeptide and irradiated tumor cells were used as the tumor vaccine (which included free lipopeptides). Although P2CSK11 and P2CSR11 showed anti-tumor effects similar to those of P2CSK4 (Figure 4A), all induced skin erosions and inflammation at the site of vaccination (in 20%, 60% and 100% of mice treated with P2CSR11, P2CSK11 and P2CSK4, respectively) (Figure 4B). Next, we examined the effects of vaccines that did not contain free lipopeptides (P2CSK4; Figure 4C, left panel; and P2CSR11; Figure 4C, right panel). BMTC prepared with P2CSK4, but not those prepared with P2CSR11, showed less anti-tumor activity after free peptide was removed; this is because P2CSK4 binds tumor cell membranes more weakly than P2CSR11 (Figure 4C). Furthermore, we examined the cytotoxic activity of lipopeptides against different tumor cells using splenocytes from treated mice. P2CSR11 induced slightly higher levels of specific CTL activity, but lower levels of NK activity, than the other lipopeptides (Figure 4D).

To ascertain the method most suitable for preparation of tumor cells for use as tumor antigens, we compared the in vivo anti-tumor effects of irradiated tumor cells (which are similar to previously reported antigen inclusion bodies comprising liposomes with adjuvant38) with those of tumor cell debris prepared by freeze/thaw methods (the simple mixture of antigens and adjuvant). In the presence of tumor cell debris, P2CSR11 generated only weak anti-tumor effects (Figure 5A). However, P2CSK4 showed similar levels of anti-tumor activity when bound to irradiated tumor cells or in the presence of tumor cell debris (Figure 5B). The anti-tumor effects of

---

**FIGURE 1** The importance of peptide sequences within lipopeptides used for tumor cell modification. A, Strategy used to generate tumor cells coated with a synthetic TLR2 ligand. A synthetic lipopeptide containing positively charged polypeptide sequences binds nonspecifically to the negatively charged tumor cell plasma membrane. Tumor cells coated with these lipopeptides, called bacteria-mimicking tumor cells (BMTC), are expected to be recognized by antigen-presenting cells. B, The characteristics, molecular weight, isoelectric point (pl) and hydrophobicity of the natural (MALP2) and synthetic (P2CSK4, P2CSK11 and P2CSR11) lipopeptides used in the study. The pl and hydrophobicity of the peptide sequences was calculated using the ProtParam tool (http://br.expasy.org/tools/protparam.html). C, Affinity of biotinylated peptides for RMA-S cells. Binding of the peptides was detected using streptavidin-APC and flow cytometry. The numbers in the panels represent the mean fluorescence intensities.
### (A) Control vs. MALP2, P2CSK4, P2CSK11, P2CSR11, LPS

| Condition | Control | MALP2 | P2CSK4 | P2CSK11 | P2CSR11 | LPS |
|-----------|---------|-------|--------|---------|---------|-----|
| Wild type | 48.7    | 93.6  | 85.1   | 96.6    | 99.7    | 149.5 |
| TLR2/−/−  | 36.0    | 39.6  | 37.6   | 37.1    | 36.4    | 140.7 |

### (B) Control vs. MALP2, P2CSK4, P2CSK11, P2CSR11, LPS

| Condition | Control | MALP2 | P2CSK4 | P2CSK11 | P2CSR11 | LPS |
|-----------|---------|-------|--------|---------|---------|-----|
| Wild type | 40.8    | 137.9 | 118.4  | 116.2   | 101.2   | 153.7 |
| TLR2/−/−  | 33.2    | 36.4  | 31.7   | 32.7    | 31.8    | 198.9 |

### (C) Control vs. MALP2, P2CSK4, P2CSK11, P2CSR11, LPS

| Condition | Control | MALP2 | P2CSK4 | P2CSK11 | P2CSR11 | LPS |
|-----------|---------|-------|--------|---------|---------|-----|
| Wild type | 18.0%   | 35.6% | 34.7%  | 35.3%   | 37.8%   | 38.4% |
| TLR2/−/−  | 20.5%   | 20.5% | 23.7%  | 18.6%   | 23.4%   | 37.2% |

### (D)

#### BMDC IL-12p40

![Graph showing IL-12p40 levels](graph)

#### Splenocytes IFN-γ

![Graph showing IFN-γ levels](graph)
BMTC coated with P2CSR11 were abolished when tested against cells from Thr2−/− mice (Figure 5C). Finally, we examined combination therapy with BMTC plus an anti-PD-L1 antibody (a known immune checkpoint inhibitor). Because TLR2 ligands stimulate IFN-γ production as shown in Figure 2D and IFN-γ induce PD-L1 expression on tumors,39 anti-PD-L1 antibody may effectively inhibit tumor growth when tumor-bearing mice are treated with TLR2 ligands. Furthermore, anti-PD-L1 antibody is reported to increase the anti-tumor effect of TLR3 ligand on an in vivo EG7-OVA transplanted model.40 We showed that anti-PD-L1 antibody increased the anti-tumor effects of BMTC coated with P2CSR11 (Figure 5D).

### 4 Discussion

Here, we showed that 2 novel synthetic lipopeptides adjuvants (P2CSR11 and P2CSK11) could be used to prepare a BMTC-based vaccine comprising tumor cells derived from a patient (a source of tumor antigens) and a TLR2 ligand. We showed that BMTC based on P2CSR11/P2CSK11: (i) stimulated DC by acting as both a tumor antigen and an immuno-adjuvant; (ii) promoted phagocytosis and cross-presentation of tumor antigen; (iii) could be purified by removing free lipopeptide; and (iv) showed a strong anti-tumor effect. Moreover, BMTC based on P2CSR11 induced less skin erosion/inflammation at the injection site, activated CTL but not NK cells, and induced a synergistic increase in the effects of immune checkpoint blockade therapy.

Although P2CSR11 induced less cytokine production than other lipopeptides in vitro (Figure 2D), BMTC coated with P2CSR11 induced efficient phagocytosis and cross-presentation (Figure 3), leading to CTL activation and a significant anti-tumor effect in an in vivo model (Figure 4). Overproduction of some cytokines can cause several adverse effects, including skin inflammation, as well as promoting anti-tumor effects. Therefore, P2CSR11 is a good candidate adjuvant for generating tumor antigen-specific immune responses with potentially fewer side effects.

Although some researchers have investigated suitable peptide sequences that may confer TLR2 ligand activity on lipopeptides,41–43 we succeeded in providing additional specific functions.9,10 Indeed, it is possible to incorporate several functions by connecting different functional peptides in tandem.44 Therefore, the selectivity and functionality of lipopeptide-based adjuvants can be improved by rearranging the peptide sequences.

Jackson et al report the use of various modified lipopeptides as anti-tumor immuno-adjuvants.45,46 A lipopeptide containing a branched cationic peptide (lysine/arginine) had affinity for negatively charged proteins and showed efficient adjuvant activity.45 To develop new tumor vaccines comprising tumor cells coated with a TLR2 ligand, we focused on cell-penetrating peptides (CPP) containing cationic sequences, such as poly-arginine and poly-lysine. The CPP, which was originally identified in the transactivator of protein human immunodeficiency virus, has an affinity for negatively charged plasma membranes comprising proteoglycans and phospholipids and is internalized via both passive and active processes.47,48 When tumor cells are used as a source of tumor antigens, cells derived from biopsy samples must first be killed by irradiation or with anti-tumor chemotherapeutic drugs to inhibit growth. In the case of killed tumor cells, active incorporation is impaired, meaning that CPP binds to the plasma membrane and is retained on the cell surface (Figure 1C). In addition, positively charged peptides like polybrene49 neutralize the negative charge on the membrane surface, meaning that tumor cells can easily come into contact with the DC membrane. Therefore, P2CSR11 promotes phagocytosis via not only TLR2 signaling but also by neutralizing the electric charge on the cell membrane. Indeed, BMTC coated with P2CSR11 showed slightly higher uptake by BMDC from Thr2−/− mice than control tumor cells lacking lipopeptides (Figure 3A). The ability of a cationic polypeptide to bind to the cell surface seems to depend on the number of cationic amino acids such as lysine and arginine.50 Because the peptide portion of P2CSR11, but not that of P2CSK4, bound efficiently to the cell membrane (Figure 1C), we surmised that the positive charge of P2CSR11 neutralized the negative charge on the cell membrane of BMTC to a greater extent than that on BMTC coated with other lipopeptides, thereby promoting contact with DC.

Although all the tested lipopeptides activated DC to a similar extent (as measured by expression of maturation markers and phagocytic activity), P2CSR11 in the absence of tumor cells induced less cytokine production than the other lipopeptides (Figure 2). Cytokines and cross-presentation are induced by TLR2-dependent
signals; however, although the lipopeptides harboring 2 palmitates (such as MALP2) activate the TLR2-TLR6 heterodimer, other groups report that P2CSK4 can activate TLR6-independent signals via the peptide component (the SK4 peptide). Therefore, we speculated that P2CSR11 might activate other signals that regulate cytokine production in an SR11 peptide-dependent manner. Alternatively, because SR11, but not SK4, binds electrostatically to the cell surface, the SR11 peptide might disturb the membrane dynamics of DC and alter cytokine production signals. However, when BMTC were coated with P2CSK11 or P2CSR11, they induced phagocytosis of tumor cells and cross-presentation of tumor antigens by DC. Moreover, BMTC coated with P2CSK11 or P2CSR11 induced higher levels of antigen-dependent IFN-γ production by OT-I splenocytes than cells coated with other lipopeptides (Figure 3C). Although BMTC coated with P2CSR11 or P2CSK11 showed stronger antitumor effects than P2CSK4 in tumor-bearing mice (Figure 4A, left and right), skin reactions at the vaccination site on EG7-OVA-bearing mice. The percentage of mice suffering skin erosion or inflammation at the vaccination site is shown. Numbers from 3 independent experiments were summed. C, Antitumor effects of BMTC after removal of free lipopeptide. Tumor cells were mixed with P2CSK4 (left) and P2CSR11 (right) for 2 h at 4°C and then washed to remove unbound lipopeptide. The BMTC were administrated intradermally twice. The in vivo data in this figures are representative of 2 experiments. D, Cytotoxic T lymphocytes (CTL) and natural killer (NK) activity induced by vaccination of tumor-bearing mice with tumor cells coated with lipopeptides. The cytotoxic activity of CTL against RMA-S cells pulsed with OVA (RMA-S+OVA) or WT1 (RMA-S+WT1) peptides, or the cytotoxic activity of NK (YAC-1) cells, is shown in EG7-OVA (left) and mWT1-C1498 (right) model mice. Data are representative of 2 independent experiments. Each point represents the mean ± SD (n = 3). *P < .05, **P < .01 (1-way ANOVA with Dunnett’s test vs control splenocytes from untreated tumor-bearing mice).
P2CSR11 induced higher antigen-dependent cytotoxic activity (but less NK-dependent cytotoxic activity) than P2CSK11 (Figure 4D). These results suggest that P2CSR11 works as a CTL-orienting adjuvant; therefore, it is a suitable candidate vaccine against CTL-sensitive tumors expressing MHC class I.

We previously reported that TLR2 ligands induce inflammation at the site of administration when used as immuno-adjuvants.9,10 Such adverse effects of new adjuvants must be considered from a clinical perspective. Although P2CSR11, P2CSK11 and P2CSK4 inhibited tumor growth in vivo mouse models to a similar extent (Figure 4), P2CSK4 and P2CSK11 induced more severe inflammation at the injection site. Because P2CSK4 is retained for long periods around the injection site,9 we predict that it is necessary to remove free lipopeptides from the vaccine to avoid such adverse effects. BMTC coated with P2CSR11 maintained anti-tumor effects after removing free lipopeptide (Figure 4C). Thus, P2CSR11 is a strong candidate as it can induce anti-tumor activity with fewer (or less severe) adverse effects.

Lipopeptides bind to TLR2 and induce DC responses. A recent study suggests that lipopeptides are incorporated into endosomes and activate the TLR2/Myd88 signaling pathway in endolysosomes, but not on the cell surface.51 Because lipopeptides stimulate TLR2 inside DC after phagocytosis, TLR2 might act as a capture receptor, and lipopeptides on the tumor cell surface might act as a marker for phagocytosis via TLR2. Unfortunately, we were unable to clarify whether TLR2 acts as a capture receptor or as a TLR2/Myd88 signaling receptor. However, TLR2 ligands increased the phagocytic activity of DC (Figure 2C), and BMDC derived from Tlr2−/− or Myd88−/− mice failed to engulf BMTC coated with P2CSR11 (Figure 3A) and failed to present antigen (Figure 3B). These findings suggest that activation of TLR2/Myd88 signaling pathway is essential for phagocytosis and antigen cross-presentation. BMTC coated with lipopeptides can activate DC via the TLR2 signaling pathway and present tumor antigen to DC at the same time; these responses might increase the total amount of antigen engulfed and promote cross-presentation.

The experiments in tumor-bearing mouse models showed that the lipopeptides (administered as a vaccine) inhibited tumor growth. However, the anti-tumor effects are weaker than those observed for nucleic acid-based adjuvants such as poly I:C.26,27,52 A previous

**FIGURE 5** Conditions essential for induction of antitumor effects by a bacteria-mimicking tumor cell vaccine based on P2CSR11. A and B, Effects of preparation method on antitumor effects. Vaccines were prepared by mixing P2CSR11 (A) or P2CSK4 (B) with irradiated tumor cells (Rad) or tumor cell debris formed by freeze/thawing cells (Deb). The numbers in parentheses indicate the total number of mice suffering skin erosions or inflammation at the vaccination site (data from 2 independent experiments). C, Antitumor effect of irradiated EG7-OVA coated with P2CSR11 in mice lacking Tlr2. D, Anti-tumor effect of combined therapy with an immune checkpoint inhibitor and bacteria-mimicking tumor cells. Anti-PD-L1 antibody (PD-L1, intraperitoneally) and P2CSR11-coated EG7-OVA cells (subcutaneously) were administrated on the indicated days (arrows). Data in this figures are representative of 2 experiments. On Day 0, EG7-OVA cells (2 × 10⁶ cell) were transplanted subcutaneously into the backs of mice. Each point represents the mean ± SE (n = 5 mice). *P < .05, **P < .01. NS, not significant (C, Student t test; all others, 1-way ANOVA with Dunnett’s test [vs each control group])
study showed that induction of the regulatory T cells by TLR2 ligands attenuates the effectiveness of a vaccine; it may be, therefore, that we have to remove such a regulatory mechanism from the immune system to improve the effectiveness of lipopeptide vaccines.\textsuperscript{53,54}

**ACKNOWLEDGMENTS**

We are grateful to H. Murakami, T. Yasuda, S. Yoshida and N. Kanto (Osaka International Cancer Institute, Osaka) for their technical assistance.

**CONFLICT OF INTEREST**

The authors have no conflict of interest to declare.

**ORCID**

Takashi Akazawa \(\text{http://orcid.org/0000-0002-4155-9228}\)

Toshimitsu Ohashi \(\text{http://orcid.org/0000-0003-2347-6709}\)

Norimitsu Inoue \(\text{http://orcid.org/0000-0002-1226-5183}\)

**REFERENCES**

1. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. *Clin Cancer Res*. 1856;2016:1856-1864.

2. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. *Clin Cancer Res*. 2013;19:5300-5309.

3. Gabriovich DI. Myeloid-derived suppressor cells. *Front Immunol*. 2017;5:3-8.

4. Italiani P, Boraschi D. From Monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. *Front Immunol*. 2014;5:514.

5. Ohashi T, Aoki M, Tomita H, et al. M2-like macrophage polarization in high lactic acid-producing head and neck cancer. *Cancer Sci*. 2017;108:1128-1134.

6. Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. *Int Immunol*. 2016;28:401-409.

7. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J*. 1992;11:3887-3895.

8. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily-CTLA-4. *Nature*. 1987;328:267-270.

9. Akazawa T, Ohashi T, Nakajima H, et al. Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation. *Int J Cancer*. 2014;135:2847-2856.

10. Akazawa T, Inoue N, Shime H, Kodama K, Matsumoto M, Seya T. Adjuvant engineering for cancer immunotherapy: development of a synthetic TLR2 ligand with increased cell adhesion. *Cancer Sci*. 2010;101:1596-1603.

11. Mühlradt PF, Kiess M, Meyer H, Süssmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from mycoplasma fermentans acting at picomolar concentration. *J Exp Med*. 1997;185:1951-1958.

12. Matsumoto M, Nishiguchi M, Kikkawa S, Nishimura H, Nagasawa S, Seya T. Structural and functional properties of complement-activating protein M161Ag, a Mycoplasma fermentans gene product that induces cytokine production by human monocytes. *J Biol Chem*. 1998;273:12407-12414.

13. Rezwan M, Grau T, Tschumi A, Sander P. Lipoprotein synthesis in mycobacteria. *Microbiology*. 2007;153:652-852.

14. Hutchings MI, Palmer T, Harrington DJ, Suttcliffe IC. Lipoprotein bio-genesis in Gram-positive bacteria: knowing when to hold ‘em, knowing when to fold ‘em. *Trends Microbiol*. 2009;17:13-21.

15. Omueti KO, Beyer JM, Johnson CM, Lyle EA, Tapping RI. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. *J Biol Chem*. 2005;280:36616-36625.

16. Kang JY, Nan X, Jin MS, et al. Recognition of lipopeptide patterns by toll-like receptor 2-toll-like receptor 6 heterodimer. *Immunity*. 2009;31:873-884.

17. Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. *Cell*. 2007;130:1071-1082.

18. Voss S, Ulmer AJ, Jung G, Wiesmüller KH, Brock R. The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers. *Eur J Immunol*. 2007;37:3489-3498.

19. Okusawa T, Fujita M, Nakamura J, et al. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. *Infect Immun*. 2004;72:1657-1665.

20. Liu SQ, Saijo K, Todokoro T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. *Nat Med*. 1995;1:267-271.

21. Ophir E, Bobišs S, Coukoss G, Harari A, Kandalaft LE. Personalized approaches to active immunotherapy in cancer. *Biochim Biophys Acta*. 2016;1865:72-82.

22. Yamasaki S, Okino T, Chakraborty NG, et al. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients. *Cancer Immunol Immunother*. 1995;40:268-271.

23. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. *Nat Med*. 2004;10:909-915.

24. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. *Science*. 2007;316:1628-1632.

25. Akazawa T, Masuda H, SaeKI Y, et al. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. *Cancer Res*. 2004;64:757-764.

26. Akazawa T, Ebihara T, Okuno M, et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1(TRIF) pathway in myeloid dendritic cells. *Proc Natl Acad Sci U S A*. 2007;104:252-257.

27. Matsumoto M, Tatematsu M, Nishikawa F, et al. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. *Nat Commun*. 2015;6:6280.

28. Kobiyama K, Aoshi T, Narita H, et al. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. *Proc Natl Acad Sci U S A*. 2014;111:3086-3091.

29. Zom GG, Welters MJ, Loof NM, et al. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. *OncoTarget*. 2016;7:67087-67100.

30. Zom GG, Khan S, Britten CM, et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. *Cancer Immunol Res*. 2014;2:756-764.

31. Nishikawa H, Sato E, Briones G, et al. In vivo antigen delivery by a *Salmonella typhimurium* type III secretion system for therapeutic cancer vaccines. *J Clin Invest*. 2006;116:1946-1954.

32. Helmich BK, Dutton RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing.
properties of Tc1 and Tc2 effectors. J Immunol. 2001;166:6500-6506.

33. Nakajima H, Oka Y, Tsuboi A, et al. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration. Vaccine. 2012;30:722-729.

34. Masuda H, Sakai Y, Nomura M, et al. High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-“pam” RAE-1 antibody confer tumor susceptibility to NK cells. Biochem Biophys Res Commun. 2002;290:140-145.

35. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985;162:1745-1759.

36. Igawa K, Kokubu C, Yusa K, et al. Removal of reprogramming transgenes improves the tissue reconstitution potential of keratinocytes generated from human induced pluripotent stem cells. Stem Cells Transl Med. 2014;3:992-1001.

37. Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005;122:473-483.

38. Gérard C, Baudson N, Ory T, Louahed J. Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumor responses. PLoS One. 2014;9:e94883.

39. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140-1145.

40. Takeda Y, Kataoka K, Yamagishi J, Ogawa S, Seya T, Matsumoto M. A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy. Cell Rep. 2017;19:1874-1887.

41. Seya T, Shime H, Takeda Y, Tatamatsu M, Matsumoto M. Adjuvant for vaccine immunotherapy of cancer-focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci. 2015;106:1659-1668.

42. Fujimoto Y, Hashimoto M, Furuyashiki M, et al. Lipopeptides from Staphylococcus aureus as Thr2 Ligands: prediction with mRNA expression, chemical synthesis, and immunostimulatory activities. ChemBioChem. 2009;10:2311-2315.

43. Azuma M, Sawahata R, Akao Y, et al. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One. 2010;5:e12550.

44. Buwitt-Beckmann U, Heine H, Wiesmüller KH, et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol. 2005;35:282-289.

45. Chua BY, Pejosi D, Turner SJ, Zeng W, Jackson DC. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. J Immunol. 2011;187:1692-1701.

46. Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004;101:15440-15445.

47. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997;272:16010-16017.

48. Brock R. The uptake of arginine-rich cell-penetrating peptides: putting the puzzle together. Bioconjug Chem. 2014;25:863-868.

49. Davis HE, Morgan JR, Yarmush ML. Polybrene increases retrovirus adsorption on target cell membranes. Biophys Chem. 2002;19:159-172.

50. Kosuge M, Takeuchi T, Nakase I, Jones AT, Futaki S. Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. Bioconjug Chem. 2008;19:656-664.

51. Motoy M, Shibata T, Takahashi K, et al. Lipopeptides are signaled by Toll-like receptor 2, 6 and 10 in endolysosomes. Int Immunol. 2014;26:563-573.

52. Azuma M, Ebihara T, Oshiumi H, Matsumoto M, Seya T. Cross-priming for antitumor CTL induced by soluble Ag + poly: C depends on the TICAM-1 pathway in mouse CD11c+CD8α+ dendritic cells. Oncoimmunology. 2012;1:581-592.

53. Yamazaki S, Okada K, Maruyama A, Matsumoto M, Yagita H, Seya T. TLR2-dependent induction of IL-10 and Foxp3+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One. 2011;6:e18833.

54. Maruyama A, Shime H, Takeda Y, Azuma M, Matsumoto M, Seya T. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochem Biophys Res Commun. 2015;457:445-450.